Clearon Inc.: 105,3%

3.4. DUMPING MARGIN

Clearon Inc. -8,1% -

USA -Biolab Inc. -7,4% -

Clearon Inc. -8,1% -A596 -

USA -Biolab Inc. -7,4% -A594 -

Clearon Inc. -28,5% -A596 -

All other companies -40,3% -A999 -

Clearon Inc. -28,5% -69,8% -28,5% -

All other companies -60,6% -40,3% -40,3% -

ΗΠΑ -Biolab Inc. -7,4% -A594 -Clearon Inc. -8,1% -A596 -

Zhucheng Taisheng Chemical Co. Limited -40,5% -A627 -

-Clearon Inc.: 69,8%.

-Clearon Inc.: 69,8%.

(38) Τα προσωρινά περιθώρια ντάμπινγκ, εκφραζόμενα ως εκατοστιαίο ποσοστό της τιμής εισαγωγής CIF στα σύνορα της Κοινότητας, πριν από την καταβολή δασμού, καθορίζονται ως εξής:BioLab Inc.: 50,4%Clearon Inc.: 105,3%(39) Το υπόλοιπο οριστικού περιθωρίου ντάμπινγκ υπολογίστηκε ως το υψηλότερο περιθώριο ντάμπινγκ που διαπιστώθηκε με βάση τον αντιπροσωπευτικό τύπο προϊόντος με το υψηλότερο ντάμπινγκ για έναν από τους συνεργασθέντες παραγωγούς-εξαγωγείς.Υπόλοιπο περιθωρίου ντάμπινγκ: 120%.

36. In this respect it is noted that the activity of the group, which in the US consists of the exporting producer and its mother company, and the costs made at that level with regard to TCCA, contribute to the marketing of both the bulk product and its different presentations to the first independent customer. The finished product is nothing more than the bulk product in a specific presentation. Claiming that the overheads do not play a role in the marketing of the bulk production would imply that it would be possible to continue the profitable production of bulk product without interference of the company and group structure, and more specifically its sales organisation. However, in reality the marketing does not distinguish between bulk or finished product but serves the marketing of TCCA in all its presentations. The claim was therefore rejected.37. In all other respects and in the absence of further comments, the provisional findings concerning the comparison of normal value to export price as set out in recital (94) of the provisional Regulation are confirmed.